Research programme: Biochronomer extended release therapeutics - Heron Therapeutics

Drug Profile

Research programme: Biochronomer extended release therapeutics - Heron Therapeutics

Alternative Names: Buprenorphine extended release - Heron Therapeutics; HTX 003; Ropivacaine extended release - Heron Therapeutics

Latest Information Update: 23 Mar 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Heron Therapeutics
  • Class Amides; Non-opioid analgesics; Small molecules
  • Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Opioid abuse; Postoperative pain

Most Recent Events

  • 01 Dec 2014 Preclinical trials in Opioid abuse in USA (SC)
  • 12 Nov 2013 Preclinical trials in Postoperative pain in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top